VEGFA and hereditary hemorrhagic telangiectasia: Several animal and clinical studies have implicated angiogenic VEGF in the pathology of HHT, which lead to the proposal of anti VEGF therapies for the management of HHT (Sadick et al., 2005; Shao et al., 2009; Choi et al., 2014).